Oragenics Inc (OGEN)

$0.38

+0.02

(+6.39%)▲

Market is closed - opens 7 PM, 10 Oct 2024

Performance

  • $0.38
    $0.40
    $0.38
    downward going graph

    0.55%

    Downside

    Day's Volatility :5.53%

    Upside

    5.0%

    downward going graph
  • $0.35
    $7.74
    $0.38
    downward going graph

    7.61%

    Downside

    52 Weeks Volatility :95.46%

    Upside

    95.09%

    downward going graph

Returns

PeriodOragenics IncIndex (Russel 2000)
3 Months
-66.04%
0.0%
6 Months
-71.65%
0.0%
1 Year
-88.99%
0.0%
3 Years
-98.97%
-20.8%

Highlights

Market Capitalization
3.1M
Book Value
- $0.05
Earnings Per Share (EPS)
-7.33
PEG Ratio
0.0
Wall Street Target Price
90.0
Profit Margin
0.0%
Operating Margin TTM
-263285.18%
Return On Assets TTM
-219.89%
Return On Equity TTM
-454.72%
Revenue TTM
7.5K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-91.3%
Gross Profit TTM
-9.9M
EBITDA
-19.6M
Diluted Eps TTM
-7.33
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Oragenics Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 23584.21%

Current $0.38
Target $90.00

Technicals Summary

Sell

Neutral

Buy

Oragenics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Oragenics Inc
Oragenics Inc
-28.3%
-71.65%
-88.99%
-98.97%
-98.59%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-12.19%
6.5%
20.85%
84.03%
245.65%
Novo Nordisk A/s
Novo Nordisk A/s
-11.15%
-6.13%
27.31%
138.21%
354.53%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
7.12%
73.95%
61.12%
32.59%
252.19%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.58%
13.46%
29.21%
155.56%
172.0%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Oragenics Inc
Oragenics Inc
NA
NA
0.0
0.0
-4.55
-2.2
NA
-0.05
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.59
26.59
1.37
45.03
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
39.73
39.73
1.79
3.39
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.56
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Oragenics Inc
Oragenics Inc
Buy
$3.1M
-98.59%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.8B
245.65%
26.59
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$522.1B
354.53%
39.73
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.2B
252.19%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$118.5B
172.0%
32.84
-4.74%

Insights on Oragenics Inc

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 131.52K → -37.65K (in $), with an average decrease of 245.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -12.74M → -2.30M (in $), with an average increase of 213.2% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 61.1% return, outperforming this stock by 150.1%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 33.1% return, outperforming this stock by 132.1%

Company Information

oragenics is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies. offerings are based on the probiora3 technology and brands include evoraplus™ is a new, one-of-a-kind probiotic mint that naturally supports gum and tooth health while freshening breath and whitening teeth. oragenics has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, in diagnostics, and in oral health.

Organization
Oragenics Inc
Employees
5
CEO
Mr. Charles L. Pope CPA
Industry
Health Technology

Discover More

FAQs